alemtuzumab

alemtuzumab /al″em-tuz′u-mab″/ , a recombinant, DNA–derived, humanized monoclonal antibody directed against the CD antigen CD52; it is administered intravenously as an antineoplastic drug in the treatment of B cell chronic lymphocytic leukemia.